Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

152 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The beneficial impact of metabolic dysfunction-associated fatty liver disease on lenvatinib treatment in patients with non-viral hepatocellular carcinoma.
Shimose S, Hiraoka A, Casadei-Gardini A, Tsutsumi T, Nakano D, Iwamoto H, Tada F, Rimini M, Tanaka M, Torimura T, Suga H, Ohama H, Burgio V, Niizeki T, Moriyama E, Suzuki H, Shirono T, Noda Y, Kamachi N, Nakano M, Kuromatsu R, Koga H, Kawaguchi T. Shimose S, et al. Hepatol Res. 2023 Feb;53(2):104-115. doi: 10.1111/hepr.13843. Epub 2022 Nov 6. Hepatol Res. 2023. PMID: 36149726
Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study.
Nakano M, Tanaka M, Kuromatsu R, Nagamatsu H, Tajiri N, Satani M, Niizeki T, Aino H, Okamura S, Iwamoto H, Shimose S, Shirono T, Koga H, Torimura T; Kurume Liver Cancer Study Group of Japan. Nakano M, et al. Among authors: shimose s. Cancer Med. 2015 Dec;4(12):1836-43. doi: 10.1002/cam4.548. Epub 2015 Oct 16. Cancer Med. 2015. PMID: 26471348 Free PMC article.
Hepatic arterial infusion chemoembolization therapy for advanced hepatocellular carcinoma: multicenter phase II study.
Nagamatsu H, Sumie S, Niizeki T, Tajiri N, Iwamoto H, Aino H, Nakano M, Shimose S, Satani M, Okamura S, Kuromatsu R, Matsugaki S, Kurogi J, Kajiwara M, Koga H, Torimura T. Nagamatsu H, et al. Among authors: shimose s. Cancer Chemother Pharmacol. 2016 Feb;77(2):243-50. doi: 10.1007/s00280-015-2892-7. Epub 2016 Jan 11. Cancer Chemother Pharmacol. 2016. PMID: 26754678 Clinical Trial.
Effects of in-hospital exercise on liver function, physical ability, and muscle mass during treatment of hepatoma in patients with chronic liver disease.
Koya S, Kawaguchi T, Hashida R, Goto E, Matsuse H, Saito H, Hirota K, Taira R, Matsushita Y, Imanaga M, Nagamatsu A, Shirono T, Shimose S, Iwamoto H, Niizeki T, Kuromatsu R, Miura H, Shiba N, Torimura T. Koya S, et al. Among authors: shimose s. Hepatol Res. 2017 Mar;47(3):E22-E34. doi: 10.1111/hepr.12718. Epub 2016 May 5. Hepatol Res. 2017. PMID: 27062043
Inhibition of hypoxia-inducible factor via upregulation of von Hippel-Lindau protein induces "angiogenic switch off" in a hepatoma mouse model.
Iwamoto H, Nakamura T, Koga H, Izaguirre-Carbonell J, Kamisuki S, Sugawara F, Abe M, Iwabata K, Ikezono Y, Sakaue T, Masuda A, Yano H, Ohta K, Nakano M, Shimose S, Shirono T, Torimura T. Iwamoto H, et al. Among authors: shimose s. Mol Ther Oncolytics. 2015 Dec 2;2:15020. doi: 10.1038/mto.2015.20. eCollection 2015. Mol Ther Oncolytics. 2015. PMID: 27119112 Free PMC article.
Alternative treatments in advanced hepatocellular carcinoma patients with progressive disease after sorafenib treatment: a prospective multicenter cohort study.
Nakano M, Tanaka M, Kuromatsu R, Nagamatsu H, Satani M, Niizeki T, Okamura S, Iwamoto H, Shimose S, Shirono T, Noda Y, Koga H, Torimura T; Kurume Liver Cancer Study Group Of Japan. Nakano M, et al. Among authors: shimose s. Oncotarget. 2016 Sep 27;7(39):64400-64409. doi: 10.18632/oncotarget.10794. Oncotarget. 2016. PMID: 27462865 Free PMC article.
152 results